ArticleLung India : official organ of Indian Chest Society2026
Prevalence of blood eosinophilia and its impact on lung functions in stable chronic obstructive pulmonary disease patients.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveChronic obstructive pulmonary disease (COPD) is marked by persistent airflow limitation. Blood eosinophilia has emerged as a potential biomarker for predicting the risk of exacerbations as well as response to inhaled corticosteroids (ICS). However, its impact on lung function in stable COPD remains uncertain. This study aimed to assess the prevalence of blood eosinophilia in stable COPD patients and explore its relationship with lung function, exercise capacity and exacerbation history.
methodsA total of 60 stable COPD patients were included in this cross-sectional study, selected according to specific inclusion and exclusion criteria. Blood eosinophil counts were measured, with eosinophilia defined as ≥2%. Lung function was evaluated through spirometry, while exercise capacity was assessed using the 6-minute walk test (6MWT). Statistical tests were applied to compare data between the eosinophilic and non-eosinophilic groups.
resultsEosinophilia was present in 21.67% of patients. Eosinophilic patients had a higher rate of exacerbations (53.85%) and a lower FEV1 (mean 39.46% predicted) as compared to non-eosinophilic patients (17.02% and 50.79%, respectively). The 6MWT distance was shorter in eosinophilic patients (249.38 meters) as compared to non-eosinophilic patients (274.17 meters).
conclusionEosinophilic inflammation in COPD significantly impacts exacerbation risk, lung function and exercise capacity . Eosinophil counts may prove to be a useful biomarker for identifying COPD patients who are more likely to benefit from targeted treatments, such as inhaled corticosteroids (ICS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.